LivaNova (NASDAQ:LIVN) Posts Quarterly Earnings Results, Beats Estimates By $0.28 EPS

LivaNova (NASDAQ:LIVN) issued its quarterly earnings data on Wednesday. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28, Briefing.com reports. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company had revenue of $294.90 million for the quarter, compared to the consensus estimate of $278.17 million. During the same quarter in the prior year, the firm earned $0.43 earnings per share. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. LivaNova updated its FY 2024 guidance to 3.050-3.150 EPS and its FY24 guidance to $3.05-3.15 EPS.

LivaNova Stock Performance

LIVN traded up $0.06 during trading hours on Thursday, hitting $62.68. 838,918 shares of the stock were exchanged, compared to its average volume of 641,330. LivaNova has a 12 month low of $42.75 and a 12 month high of $63.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The stock has a 50-day simple moving average of $54.44 and a 200-day simple moving average of $50.85. The stock has a market cap of $3.39 billion, a price-to-earnings ratio of 195.69 and a beta of 0.92.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LIVN. StockNews.com raised shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Robert W. Baird boosted their price objective on shares of LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a research note on Thursday. Barclays upped their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Mizuho upped their price objective on shares of LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of LivaNova in a report on Wednesday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $66.20.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.